In sarcomas, studies have evaluated the expression levels of PD-L1 in osteosarcomas and soft tissue sarcomas, but patients with high PD-L1 expressions did not achieve better outcomes after receiving immunotherapy44–46. This evidence concerns the gene CD274 and soft tissue sarcoma.